4502.T
Latest Trade
3,842.00JPYChange
--(--)Today's Range
-
--52 Week Range
-
4,822.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Oct 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS TO ACINO FOR OVER $200 MILLION USD.ENTERED DEAL TO DIVEST PORTFOLIO OF SELECT OTC & PRESCRIPTION PHARMACEUTICAL ASSETS IN NEMEA TO ACINO FOR IN EXCESS OF $200 MILLION.INTENDS TO USE DEAL PROCEEDS TO REDUCE DEBT, CONTINUE TO DELEVERAGE TOWARDS TARGET OF 2.0X NET DEBT/ADJUSTED EBITDA OVER NEXT 3 TO 5 YRS.UNDER TERMS OF AGREEMENT, ACINO WILL ACQUIRE RIGHTS, TITLE, INTEREST TO PRODUCTS IN PORTFOLIO EXCLUSIVE TO NEMEA COUNTRIES.HAS AGREED TO SELL PORTFOLIO OF ABOUT 30 SELECT PRESCRIPTION PHARMACEUTICAL AND OTC PRODUCTS SOLD IN NEMEA REGION TO ACINO.IT IS ANTICIPATED THAT PRIMARILY SALES AND MARKETING PROFESSIONALS SUPPORTING PORTFOLIO WILL TRANSITION TO ACINO AT CLOSING OF TRANSACTION.PARTIES WILL ENTER MULTI-YEAR MANUFACTURING AND SUPPLY AGREEMENT, IN WHICH TAKEDA WILL CONTINUE TO MANUFACTURE PRODUCTS ON BEHALF OF ACINO.TRANSACTION IS EXPECTED TO CLOSE IN Q4 FY19.
Oct 14 (Reuters) - ImaginAb::IMAGINAB SIGNS MULTI-PARTY COLLABORATION AGREEMENT WITH 3 GLOBAL PHARMACEUTICAL COS TO HELP FURTHER DEVELOP CO'S CD8 IMMUNOPET TECHNOLOGY.ANNOUNCED SIGNING OF MULTI-PARTY AGREEMENT WITH ASTRAZENECA, PFIZER, TAKEDA PHARMACEUTICAL.COLLABORATORS TO HELP GUIDE IMAGINAB-SPONSORED CLINICAL TRIAL AIMING TO EVALUATE UTILITY, VALUE OF CD8 IMMUNOPET IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT.COLLABORATORS WILL GAIN EARLY ACCESS TO CLINICAL & IMAGING DATA & COLLECTIVELY CONTRIBUTE TO POST-TRIAL DATA ANALYSIS.
Sept 27 (Reuters) - Cerveau Technologies Inc::CERVEAU TECHNOLOGIES INC. SIGNS RESEARCH AGREEMENT WITH TAKEDA TO PROVIDE NOVEL TAU IMAGING AGENT.CERVEAU TECHNOLOGIES -WITH COLLABORATION, TAKEDA TO USE CO'S INVESTIGATIONAL IMAGING AGENT IN PET SCANS TO ASSESS STATUS, PROGRESSION OF NFTS IN BRAIN.
Sept 24 (Reuters) - Evotec Se <EVTG.DE>::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.
Sept 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ISSUES US RECALL OF NATPARA® (PARATHYROID HORMONE) FOR INJECTION DUE TO THE POTENTIAL FOR RUBBER PARTICULATE.TAKEDA - RECALL IS EFFECTIVE IMMEDIATELY DUE TO POTENTIAL ISSUE RELATED TO RUBBER PARTICULATES ORIGINATING FROM RUBBER SEPTUM OF NATPARA CARTRIDGE.TAKEDA PHARMACEUTICAL CO LTD - RECALL IS BEING CONDUCTED AFTER DISCUSSIONS WITH FDA.
Sept 3 (Reuters) - Kamada Ltd <KMDA.TA>::KAMADA ANNOUNCES EXTENSION OF GLASSIA® [ALPHA1-PROTEINASE INHIBITOR (HUMAN)] SUPPLY AND DISTRIBUTION AGREEMENT WITH TAKEDA THROUGH 2021 AND EXPECTED TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA.KAMADA LTD - KAMADA WILL NOW CONTINUE TO PRODUCE GLASSIA FOR TAKEDA THROUGH 2021.KAMADA LTD - PROJECTS TOTAL REVENUES FROM SALES OF GLASSIA TO TAKEDA DURING YEARS 2019-2021 WILL BE IN RANGE OF $155 MILLION TO $180 MILLION.KAMADA LTD - REITERATING ITS FULL-YEAR 2019 REVENUE GUIDANCE OF $125 MILLION TO $130 MILLION.KAMADA LTD - PLANS TO PROVIDE ITS 2020 REVENUE GUIDANCE BY END OF 2019.
Aug 8 (Reuters) - Kamada Ltd <KMDA.TA>::KAMADA REPORTS DISCUSSIONS WITH TAKEDA REGARDING A POTENTIAL EXTENSION OF THE PERIOD FOR THE TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA.KAMADA LTD - GLASSIA SUPPLY AGREEMENT WITH TAKEDA CURRENTLY EXTENDS THROUGH END OF 2020.KAMADA LTD - TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA AFTER 2020 WILL RESULT IN A SIGNIFICANT REDUCTION OF KAMADA'S REVENUES.KAMADA LTD - BASED ON CURRENT TERMS OF SUPPLY AGREEMENT, KAMADA WOULD BE ENTITLED TO FUTURE ROYALTY PAYMENTS UNTIL 2040..
Aug 5 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES AND TAKEDA ENTER INTO NEW STRATEGIC MULTI-TARGET RESEARCH, DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP.CO IS ELIGIBLE TO RECEIVE UP TO $26 MILLION IN UPFRONT, NEAR-TERM PAYMENTS, IN ADDITION TO RESEARCH FUNDING OVER AGREEMENT TERM.
July 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::INVESTIGATIONAL SUBCUTANEOUS FORMULATION OF VEDOLIZUMAB MEETS PRIMARY ENDPOINT IN ACHIEVING CLINICAL REMISSION AT WEEK 52 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE.VEDOLIZUMAB SUBCUTANEOUS CURRENTLY UNDER REVIEW FOR APPROVAL FOR ULCERATIVE COLITIS WITH EUROPEAN MEDICINES AGENCY, U.S. FDA.
July 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::HEALTH CANADA HAS AUTHORIZED VYVANSE® (LISDEXAMFETAMINE DIMESYLATE), THE FIRST AND ONLY, CHEWABLE TABLET FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)1*.TAKEDA CANADA - HEALTH CANADA HAS AUTHORIZED A CHEWABLE TABLET OF VYVANSE.TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE INDICATED FOR TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER IN ADULTS AGED 18 AND OLDER.TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE EXPECTED TO BE AVAILABLE IN FALL 2019..
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.